Search results for "40"

showing 10 items of 17345 documents

Squaric Acid-Based Radiopharmaceuticals for Tumor Imaging and Therapy.

2021

Targeting vectors bound to a chelator represent a significant fraction of radiopharmaceuticals used nowadays for diagnostic and therapeutic purposes in nuclear medicine. The use of squaramides as coupling units for chelator and targeting vector helps to circumvent the disadvantages of several common coupling methods. This review gives an overview of the use of squaric acid diesters (SADE) as linking agents. It focuses on the conjugation of cyclic chelators, e.g., DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), as well as hybrid chelators like AAZTA5 (6-pentanoic acid-6-amino-1,4-diazepine tetracetic acid) or DATA5m (6-pentanoic acid-6-amino-1,4-diazapine-triacetate) to diff…

medicine.drug_classBiomedical EngineeringPharmaceutical ScienceBioengineering02 engineering and technologySquaric acidMonoclonal antibody01 natural scienceschemistry.chemical_compoundFibroblast activation protein alphaIn vivoNeoplasmsmedicineDOTAHumansChelationPharmacology010405 organic chemistryChemistryOrganic Chemistry021001 nanoscience & nanotechnologyCombinatorial chemistrySmall molecule0104 chemical sciencesPositron-Emission TomographyRadiopharmaceuticals0210 nano-technologyCyclobutanesBiotechnologyConjugateBioconjugate chemistry
researchProduct

Synthesis and biological evaluation of sphingosine kinase 2 inhibitors with anti-inflammatory activity.

2019

The synthesis of inhibitors of SphK2 with novel structural scaffolds is reported. These compounds were designed from a molecular modeling study, in which the molecular interactions stabilizing the different complexes were taken into account. Particularly interesting is that 7‐bromo‐2‐(2‐phenylethyl)‐2,3,4,5‐tetrahydro‐1,4‐epoxynaphtho[1,2‐b]azepine, which is a selective inhibitor of SphK2, does not exert any cytotoxic effects and has a potent anti‐inflammatory effect. It was found to inhibit mononuclear cell adhesion to the dysfunctional endothelium with minimal impact on neutrophil–endothelial cell interactions. The information obtained from our theoretical and experimental study can be us…

medicine.drug_classCell SurvivalNeutrophilsFísico-Química Ciencia de los Polímeros ElectroquímicaCellAnti-Inflammatory AgentsPharmaceutical ScienceSYNTHESIS01 natural sciencesPeripheral blood mononuclear cellAnti-inflammatoryANTI-INFLAMMATORY ACTIVITYchemistry.chemical_compoundStructure-Activity RelationshipDrug DiscoverymedicineCell AdhesionHuman Umbilical Vein Endothelial CellsCytotoxic T cellHumansMOLECULAR MODELINGAzepineEnzyme Inhibitors010405 organic chemistryBIOASSAYSCiencias QuímicasSphingosine Kinase 2AdhesionAzepines0104 chemical sciencesMolecular Docking Simulation010404 medicinal & biomolecular chemistrySPHK2Phosphotransferases (Alcohol Group Acceptor)medicine.anatomical_structurechemistrySPHINGOSINE KINASE 2 INHIBITORSDrug DesignCancer researchEpoxy CompoundsEndothelium VascularCIENCIAS NATURALES Y EXACTASProtein BindingArchiv der Pharmazie
researchProduct

Rationally designed haptens for highly sensitive monoclonal antibody-based immunoanalysis of fenhexamid.

2018

Immunochemical methods have been consolidated during the last few years as complementary analytical strategies for chemical contaminant and residue determination. However, generation of suitable immunoreagents for small organic molecules demands adequate hapten design. In this study, fenhexamid was considered as a model compound and novel haptens were designed and synthesized in order to evaluate the influence of the linker tethering site on antibody binding properties and immunoassay parameters. Haptens were conceived with the spacer arm at different positions, while the more antigenic aromatic moiety was kept free. The synthesis of these functionalized compounds was accomplished by total …

medicine.drug_classEnzyme-Linked Immunosorbent AssayTandem mass spectrometryQuechersMonoclonal antibody01 natural sciencesBiochemistryAnalytical ChemistryLimit of DetectionElectrochemistrymedicineEnvironmental ChemistrySpectroscopyDetection limitResidue (complex analysis)Chromatographymedicine.diagnostic_test010405 organic chemistryChemistry010401 analytical chemistryAntibodies MonoclonalRepeatabilityAmides0104 chemical sciencesFungicides IndustrialImmunoassayHaptenHaptensThe Analyst
researchProduct

Macrolides May Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Entry into Cells: A Quantitative Structure Activity Relationship Study and Exp…

2021

The global pandemic caused by the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is threatening the health and economic systems worldwide. Despite the enormous efforts of scientists and clinicians around the world, there is still no drug or vaccine available worldwide for the treatment and prevention of the infection. A rapid strategy for the identification of new treatments is based on repurposing existing clinically approved drugs that show antiviral activity against SARS-CoV-2 infection. In this study, after developing a quantitative structure activity relationship analysis based on molecular topology, several macrolide antibiotics are identified as promising SARS-…

medicine.drug_classGeneral Chemical EngineeringvirusesQuantitative Structure-Activity RelationshipDiseaseLibrary and Information Sciencesmedicine.disease_causeAzithromycin01 natural sciencesAntiviral AgentsVirusArticleMacrolide AntibioticsViral life cycleClarithromycin0103 physical sciencesPandemicmedicineHumansCoronavirus010304 chemical physicsbusiness.industrySARS-CoV-2COVID-19General ChemistryVirology3. Good health0104 chemical sciencesComputer Science ApplicationsAnti-Bacterial Agents010404 medicinal & biomolecular chemistryPharmaceutical PreparationsSpike Glycoprotein CoronavirusMacrolidesbusinessmedicine.drugJournal of Chemical Information and Modeling
researchProduct

Non-covalent interactions of N-phenyl-1,5-dimethyl-1H-imidazole-4-carboxamide 3-oxide derivatives—a case of intramolecular N-oxide hydrogen bonds

2017

The crystal structures of new N-phenyl-1,5-dimethyl-1H-imidazole-4-carboxamide 3-oxide derivatives are reported. The results of X-ray diffraction showed the existence of intramolecular hydrogen bonding between carboxamide nitrogen donors and N-oxide oxygen acceptors. The use of Quantum Theory of Atoms in Molecules allowed its classification as a strong interaction, with energy about 10 kcal/mol, and of intermediate character between closed shell and shared bonds. Comparison of experimental data and quantum theoretical calculations indicated that a substituent attached to the phenyl ring in the para position influences the strength and geometry of the title hydrogen bonding. Stronger π-elect…

medicine.drug_classLow-barrier hydrogen bondintramolecular hydrogen bondSubstituentCarboxamideN-oxide group010402 general chemistry01 natural scienceschemistry.chemical_compoundComputational chemistrymedicineNon-covalent interactionsHirshfeld surface analysisPhysical and Theoretical Chemistrychemistry.chemical_classification010405 organic chemistryHydrogen bondIntermolecular forceAtoms in moleculesCondensed Matter Physicshydrogen bonding0104 chemical sciencesCrystallographychemistryQTAIMIntramolecular forcesubstituent effectStructural Chemistry
researchProduct

Structure, Biosynthesis, and Bioactivity of Photoditritide from Photorhabdus temperata Meg1

2019

A new cyclic peptide photoditritide (1), containing two rare amino acid d-homoarginine residues, was isolated from Photorhabdus temperata Meg1 after the nonribosomal peptide synthetase encoding gene pdtS was activated via promoter exchange. The structure of 1 was elucidated by HR-MS and NMR experiments. The absolute configurations of amino acids were determined according to the advanced Marfey's method after hydrolysis of 1. Bioactivity testing of 1 revealed potent antimicrobial activity against Micrococcus luteus with an MIC value of 3.0 μM and weak antiprotozoal activity against Trypanosoma brucei rhodesiense with an IC50 value of 13 μM. Additionally, the biosynthetic pathway of 1 was als…

medicine.drug_classPharmaceutical Science01 natural sciencesAnalytical Chemistrychemistry.chemical_compoundHydrolysisBiosynthesisNonribosomal peptideDrug DiscoverymedicinePharmacologychemistry.chemical_classificationbiology010405 organic chemistryOrganic ChemistryTrypanosoma brucei rhodesiensebiology.organism_classificationCyclic peptide0104 chemical sciencesAmino acid010404 medicinal & biomolecular chemistryComplementary and alternative medicinechemistryBiochemistryAntiprotozoalMolecular MedicineMicrococcus luteusJournal of Natural Products
researchProduct

Targeting a Targeted Drug: An Approach Toward Hypoxia-Activatable Tyrosine Kinase Inhibitor Prodrugs

2016

Tyrosine kinase inhibitors (TKIs), which have revolutionized cancer therapy over the past 15 years, are limited in their clinical application due to serious side effects. Therefore, we converted two approved TKIs (sunitinib and erlotinib) into 2-nitroimidazole-based hypoxia-activatable prodrugs. Kinetics studies showed very different stabilities over 24 h; however, fast reductive activation via E. coli nitroreductase could be confirmed for both panels. The anticancer activity and signaling inhibition of the compounds against various human cancer cell lines were evaluated in cell culture. These data, together with molecular docking simulations, revealed distinct differences in the impact of …

medicine.drug_classPharmacology010402 general chemistry01 natural sciencesBiochemistryArticleTyrosine-kinase inhibitor03 medical and health sciencesNitroreductase0302 clinical medicinetyrosine kinase inhibitorsDrug DiscoverymedicinecancerEpidermal growth factor receptorGeneral Pharmacology Toxicology and PharmaceuticsPharmacologybiologyhypoxiaSunitinibChemistryOrganic ChemistryProdrugtargeted therapeutic0104 chemical sciencesSettore CHIM/03 - Chimica Generale E InorganicaCell culture030220 oncology & carcinogenesisbiology.proteinMolecular MedicineErlotinibprodrugTyrosine kinasemedicine.drugChemMedChem
researchProduct

Structural, Thermodynamic, and Kinetic Traits of Antiestrogen-Compounds Selectively Targeting the Y537S Mutant Estrogen Receptor α Transcriptional Ac…

2019

The most frequently diagnosed cancers in women are the estrogen receptor (ER)-positive breast cancer subtypes, which are characterized by estrogen dependency for their growth. The mainstay of clinical treatment for this tumor relies on the modulation of ER action or on the suppression of estrogen biosynthesis via the administration of Selective ERα Modulators/Down-regulators (SERMs/SERDs) or aromatase inhibitors, respectively. Nevertheless, de novo and acquired resistance to these therapies frequently occurs and represents a major clinical concern for patient survival. Recently, somatic mutations affecting the hormone-binding domain of ERα (i. e. Y537S, Y537N, D538G) have been associated w…

medicine.drug_classSomatic cellIn silicoEstrogen receptor-02 engineering and technology010402 general chemistry01 natural scienceslcsh:ChemistryBreast cancerbreast cancermedicineAromataseresistant breast cancersOriginal ResearchbiologyChemistryWild typeY537SGeneral Chemistry021001 nanoscience & nanotechnologyAntiestrogenmedicine.diseaseSERMmolecular dynamics0104 chemical sciencesChemistrylcsh:QD1-999EstrogenSERDbiology.proteinCancer research0210 nano-technologyestrogen receptorFrontiers in chemistry
researchProduct

Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib

2019

Despite the huge success of tyrosine kinase inhibitors as anticancer agents, severe side effects are a major problem. In order to overcome this drawback, the first hypoxia-activatable 2-nitroimidazole-based prodrugs of the clinically approved ALK and c-MET inhibitor crizotinib were developed. The 2-aminopyridine functionality of crizotinib (essential for target kinase binding) was considered as ideal position for prodrug derivatization. Consequently, two different prodrugs were synthesized with the nitroimidazole unit attached to crizotinib either via carbamoylation (A) or alkylation (B) of the 2-aminopyridine moiety. The successful prodrug design could be proven by docking studies and a dr…

medicine.drug_classTyrosine kinase inhibitorAntineoplastic Agents01 natural sciencesBiochemistryArticleTyrosine-kinase inhibitorStructure-Activity Relationshipchemistry.chemical_compoundDrug DevelopmentCrizotinibIn vivoDrug DiscoverymedicineHumansAnaplastic Lymphoma KinaseProdrugsHypoxiaProdrugProtein Kinase InhibitorsMolecular BiologyCells CulturedCell ProliferationNitroimidazoleDose-Response Relationship DrugMolecular StructureCrizotinib010405 organic chemistryChemistryNitroimidazoleOrganic ChemistryProto-Oncogene Proteins c-metProdrugCell Hypoxia0104 chemical sciences010404 medicinal & biomolecular chemistrySettore CHIM/03 - Chimica Generale E InorganicaDocking (molecular)Cancer researchDrug Screening Assays AntitumorKinase bindingTyrosine kinasemedicine.drugBioorganic Chemistry
researchProduct

Humoral immunotherapy of multiple myeloma: perspectives and perplexities

2010

IMPORTANCE OF THE FIELDS Multiple myeloma (MM) is a hematological malignancy still remaining incurable despite the various therapies available, mainly because of the high fraction of refractory/relapsing cases. Therefore, the development of novel therapeutic approaches is urgently needed to overcome conventional treatment resistance. AREAS COVERED IN THIS REVIEW: In the era of targeted therapies, treatments combining a high specificity for neoplastic cells and the capability to interfere with environmental signals should be regarded as the weapons of choice. Monoclonal antibody (mAb)-based humoral immunotherapy could satisfy both these requirements when applied to MM. Indeed, many of the mo…

medicine.drug_classmedicine.medical_treatmentClinical BiochemistryCD38Monoclonal antibodyAntigens NeoplasmDrug DiscoverymedicineAnimalsHumansMultiple myelomamultiple myeloma; immunotherapyPharmacologyCD40biologybusiness.industryConventional treatmentAntibodies MonoclonalImmunotherapymedicine.diseaseImmunity Humoralmultiple myelomamultiple myeloma humoral immunotherapyHematological malignancyImmunologyMolecular targetsbiology.proteinimmunotherapybusiness
researchProduct